1. Most Discussed
  2. Gainers & Losers
SPL $1.13

human trials

  1. evo1

    303 Posts.

    Starpharma Announces Alliance with IDT Ltd to Conduct Human Trials MELBOURNE 16 SEPTEMBER 2003: Starpharma Pooled Development Limited (ASX:SPL) today announced the signing of a clinical trial agreement with Victorian-based company, Institute of Drug Technology Australia Limited (IDT). IDT will conduct Phase I human clinical trials on Starpharma’s vaginal microbicide SPL7013 gel (VivaGel) at CMAX, their Adelaide based clinical trial unit. Starpharma received clearance by the United States Food and Drug Administration (FDA) on the 31st of July 2003 to commence clinical trials on VivaGel, following its successful Investigational New Drug Application. The active component in VivaGel is SPL7013, a dendrimer based nanodrug which inhibits the HIV infection process by preventing the attachment of the virus to healthy cells. Studies in monkeys have shown complete inhibition of SHIV (a virus related closely to HIV) infection using a gel containing 5% of the active component. SPL7013 has also been shown in animal studies to prevent the infection of genital herpes and Chlamydia. Dr Raff, the CEO of Starpharma, said: “An effective vaginal microbicide would empower women to privately protect themselves from potential HIV infection”. Dr Raff said: “Starpharma investigated a range of options world-wide before deciding on IDT’s CMAX facilities in Adelaide. CMAX has previously been audited by the FDA and we believe it is a world class facility. We are pleased to be able to conduct our first clinical trialling activities in Australia.” Starpharma has an established relationship with IDT, who has worked with Starpharma and become the world’s first pharmaceutical chemistry facility to undertake dendrimer based synthesis to GMP standards. In addition to the clinical trials expertise of CMAX the principal investigator, Dr John O’Loughlin, has many years’ experience in clinical research. His experience in the use of colposcopy will be important in demonstrating the safety of SPL7013 gel (VivaGel). The Phase I studies will commence immediately after ethics approval and the enrolment of healthy women volunteers. Dr Graeme Blackman, Managing Director and Chairman of the Board of IDT, said: “Starpharma’s SPL7013 has created a significant precedent, being the first dendrimer based drug to receive clearance to commence clinical trials by the FDA. We are delighted that Starpharma has commissioned CMAX to undertake the initial Phase I trials on its new drug candidate.” Starpharma Pooled Development Limited (ASX:SPL) is a registered pooled development fund with investments in wholly owned subsidiary biopharmaceutical companies focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. SPL also has a 49.9% equity in a US based company – Dendritic Nanotechnologies Inc. (DNT) – established with the US pioneer of dendrimer nanotechnology Dr Donald Tomalia. Institute of Drug Technology Australia Limited (ASX:IDT) provides a comprehensive range of consultancy, research and development, and manufacturing services to the pharmaceutical and biotechnology sectors both in Australia and internationally. The company employs over 120 scientists in Melbourne and is licensed by the Australian Therapeutic Goods Administration (TGA) and the United States Food and Drug Administration (FDA) for production of active pharmaceutical ingredients. IDT Page 1 of 2
    Page 2 of 2
    offers early stage clinical trial services from its base at the Royal Adelaide Hospital through its CMAX division. CONTACTS: Starpharma: IDT Limited: Dr John Raff Dr Graeme Blackman Chief Executive Officer Chairman and Managing Director +61 3 8532 2701 +61 3 9801 8888 www.idtaus.com.au Mr Ben Rogers Company Secretary +61 3 8532 2702 www.starpharma.com

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.